🧪
hypothesis

Circadian Rhythm Amplification to Restore Network Oscillation Synchronization

Hypothesis

Circadian Rhythm Amplification to Restore Network Oscillation Synchronization

Circadian Rhythm Amplification to Restore Network Oscillation Synchronization.
🧬 Circadian Rhythm Amplification🩺 connectomics🎯 Composite 35%💱 $0.46▲34.0%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 5 support 5 oppose
⚠ Missing Evidence⚠ Thin Description Senate Quality Gates →
Mechanistic 0.45 (15%) Evidence 0.35 (15%) Novelty 0.65 (12%) Feasibility 0.20 (12%) Impact 0.35 (12%) Druggability 0.25 (10%) Safety 0.45 (8%) Competition 0.50 (6%) Data Avail. 0.45 (5%) Reproducible 0.40 (5%) KG Connect 0.50 (8%) 0.349 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite35%

🧪 Overview

Circadian Rhythm Amplification to Restore Network Oscillation Synchronization

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Circadian Rhythm<br/>Amplification Intervention"]
    B["SCN Pacemaking Neurons<br/>Oscillation Strength"]
    C["Network Oscillation<br/>Synchronization Restored"]
    D["BMAL1/CLOCK<br/>Clock Gene Activation"]
    E["Sleep-Wake Cycle<br/>Normalization"]
    F["Neurodegeneration<br/>Progression Slowed"]
    G["Circadian Amplification<br/>as Network Stabilizer"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    G -.->|"sustains"| B
    style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix5 supports5 contradicts
Supports
Circadian dysfunction is bidirectional with AD - disruption increases risk, pathology disrupts rhythms
PMID:28934252
Supports
Glymphatic Aβ clearance occurs primarily during sleep and is activity-dependent
PMID:24317693
Supports
Hub regions show high metabolic activity and are preferentially affected by circadian disruption
PMID:20644199
Supports
RORα agonists activate circadian target genes and show neuroprotective effects
PMID:23954313
Supports
Suvorexant (orexin antagonist) showed modest amyloid biomarker improvement in Phase 2
PMID:NCT02727959
Contradicts
RORα agonist SR1078 developed for cancer - no brain penetration data, no AD validation
PMID:23954313
Contradicts
BMAL1 is not druggable - transcription factor without ligand-binding pocket
PMID:23954313
Contradicts
Melatonin and sleep hygiene interventions failed to demonstrate disease-modifying effects
PMID:28934252
Contradicts
Glymphatic relevance in humans - and in AD - remains controversial
PMID:31501667
Contradicts
Circadian disruption may be biomarker, not cause - downstream of AD pathology
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — CIRCADIAN

No curated PDB or AlphaFold mapping for CIRCADIAN yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for Circadian Rhythm Amplification →

No DepMap CRISPR Chronos data found for Circadian Rhythm Amplification.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Rising
7d Momentum
▲ 1.6%
Volatility
Low
0.0157
Events (7d)
3
Price History
▲34.0%

💾 Resource Usage

LLM Tokens
47,826
$0.1435
Total Cost
$0.1435

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we stratify participants based on circadian amplitude quartiles (bottom 25% vs top 25%) using 14-day ambulatory actigraphy monitoring, THEN the low circadian amplitude subgroup will exhibit reducedLow circadian amplitude group shows ≥25% lower beta-band coherence (frontal-to-temporal) and ≥30% lower theta-gamma coupling index relative to high amplitude gr— no observation —pending0.45
IF we pharmacologically amplify circadian rhythm amplitude using timed melatonin receptor agonists (e.g., tasimelteon) combined with morning bright light therapy in adults aged 55-75 with documented nMean PLV increase of ≥0.15 in the 0.1-0.4 Hz frequency band measured via high-density EEG during working memory tasks— no observation —pending0.50
🔮 Falsifiable Predictions (2)
pendingconf 50%
IF we pharmacologically amplify circadian rhythm amplitude using timed melatonin receptor agonists (e.g., tasimelteon) combined with morning bright light therapy in adults aged 55-75 with documented network oscillation desynchronization, THEN we will observe a statistically significant increase in g
Predicted outcome: Mean PLV increase of ≥0.15 in the 0.1-0.4 Hz frequency band measured via high-density EEG during working memory tasks
Falsification: No significant difference in PLV between intervention and sham groups (p > 0.05, Cohen's d < 0.3), or PLV change < 0.08 in intervention arm
pendingconf 45%
IF we stratify participants based on circadian amplitude quartiles (bottom 25% vs top 25%) using 14-day ambulatory actigraphy monitoring, THEN the low circadian amplitude subgroup will exhibit reduced inter-regional beta band (13-30 Hz) coherence during REM sleep and reduced theta-gamma coupling dur
Predicted outcome: Low circadian amplitude group shows ≥25% lower beta-band coherence (frontal-to-temporal) and ≥30% lower theta-gamma coupling index relative to high am
Falsification: No significant between-group difference in beta-band coherence (t < 2.0, p > 0.05) or theta-gamma coupling (difference < 10%), OR correlation between circadian amplitude and network metrics r < 0.2
View on SciDEX ↗